Every research-peptide brand hits the same wall: the payment layer that everyone else in ecommerce uses is closed to you, and the alternatives aren't obvious.
Here's the honest map of what works, what doesn't, and how to choose between the two paths that actually hold.
- Mainstream aggregators are not an option. Stripe, PayPal, Square and Shopify Payments all restrict this category regardless of instant approval at signup.
- Two paths work: a properly underwritten high-risk merchant account, or inquiry-based ordering with no public checkout.
- How you apply matters more than who you apply to. Accurate disclosure is what separates a stable account from a six-month fund hold.
- Compare processors on total cost including reserve structure, not headline rate.
- Many mature brands run both — card checkout for standard orders, invoicing for large ones.
What doesn't work
| Provider | Position | What happens |
|---|---|---|
| Stripe | Research chemicals and unapproved substances are on the restricted businesses list | Instant signup, later review, balance held, account closed |
| PayPal | Acceptable use policy restricts this territory | Holds are common and can run long |
| Square | Prohibited goods list covers comparable ground | Same pattern |
| Shopify Payments | Prohibited business list covers the category — and Shopify's platform policy separately restricts what you can list | Payments disabled, and the store itself is exposed |
The trap is uniform across all four: onboarding is automated, underwriting isn't. You can sign up in minutes because no human reviewed anything. Review happens later, triggered by volume, disputes, a partner inquiry, or a routine sweep — and it correlates with growth, so enforcement tends to land during your best month.
Stripe's restricted businesses list and research peptides covers that pattern in detail.
Path 1 — A high-risk merchant account
A merchant account underwritten deliberately for this category, through a processor working with a sponsor bank comfortable with it.
What you get: a real approval. Someone assessed your business knowing what you sell and said yes. There's nothing left to discover later, which is precisely the point.
What it costs: meaningfully higher effective rates than aggregator headline pricing, possible application and setup fees, monthly account and gateway fees, per-chargeback fees, and a reserve.
What's required: a registered entity, business bank account, 3–6 months of statements, ownership documentation, a finished and compliance-clean website, policy pages, real contact details, and an honest answer on any prior termination.
Approval timeline: days to a few weeks, driven mostly by how fast you supply documents. Applications stall on missing paperwork far more often than on the category.
High-risk peptide merchant accounts is the full underwriting guide.
Path 2 — Inquiry-based ordering
No public card checkout at all. Researchers request a quote, you review the account, and you invoice.
What you get: nothing to freeze. There's no processor sitting on your storefront, which removes the single largest failure mode in the category outright.
What it costs: friction, and a slower funnel. Fewer people complete a quote request than complete a checkout, and you carry manual work per order.
What it doesn't cost you: search visibility. The public site still has crawlable product, category and resource pages — the SEO works exactly the same. This surprises people who assume removing checkout means removing the storefront.
Where it fits best: higher average order values, B2B and reseller volume, and founders who've already been frozen once and aren't willing to repeat it.
The inquiry-based ordering model covers the operational build.
Choosing between them
| High-risk account | Inquiry-based | |
|---|---|---|
| Conversion speed | Fast — standard checkout | Slower — manual step per order |
| Freeze exposure | Real, but managed by proper underwriting | Effectively removed |
| Setup time | Days to weeks for approval | Can be live quickly |
| Ongoing cost | Higher rates plus reserve | Your time per order |
| Cash flow | Reserve holds part of revenue for months | Invoice terms under your control |
| Best for | Higher volume, lower order value | Higher order value, B2B, post-shutdown rebuilds |
Most mature operations end up running both: card checkout for standard orders, an inquiry path for large or unusual volume. That's usually the right end state, and there's no reason to treat it as an either/or decision permanently.
How to compare specific processors
When you're evaluating high-risk providers, headline rate is the least useful number. Ask about:
- Reserve percentage, and whether it's capped. Uncapped rolling reserves scale with growth — the wrong direction.
- Release schedule in days. 90 versus 180 is a large cash-flow difference at the same percentage.
- What triggers a reserve increase, specified rather than left to discretion.
- Written conditions for reducing it after clean history. If a rep says "we usually drop that after six months", get it in the agreement.
- Chargeback fees per incident, and the ratio thresholds that trigger review.
- Settlement timing — daily, weekly, or longer.
- Gateway compatibility with what you're building.
- Who actually answers when something goes wrong.
Rolling reserves covers modelling the hold against your inventory cycle — the calculation that catches founders in month four.
What about crypto?
It comes up constantly, so: it works as a secondary option and rarely as your only one.
Upside: no chargebacks, no processor to freeze it, and some buyers in this space prefer it.
Downside: a much smaller pool of willing buyers, price volatility between order and settlement, refund friction, accounting and tax complexity, and — importantly — it doesn't remove your need for a compliant storefront. Offering crypto alongside a properly underwritten account is reasonable. Building the business on it alone constrains your market severely.
Whatever you choose, the storefront has to hold up
Both paths depend on the same foundation:
- Owned infrastructure. Platform policy and payment policy are separate enforcement systems. Solving one doesn't solve the other — see why peptide stores get shut down.
- RUO framing everywhere. Product pages, categories, blog, alt text. Underwriters read content before approving.
- Policies that exist and are honoured. Refund, shipping, privacy, terms, reachable from the footer.
- Chargeback hygiene. Recognisable billing descriptor, tracked shipping, fast support, signature confirmation on high-value orders. Your dispute ratio decides your reserve terms.
The takeaway
There is no processor that lets a research-peptide brand pay aggregator rates with aggregator convenience. That option doesn't exist, and the ones advertising it are the ones that freeze you later.
What exists is a properly underwritten account that costs more and holds, or an inquiry model that costs friction and can't be frozen. Both work. Both require an accurately described business and a storefront that survives being read by a stranger.
Pick the one that fits your order values and your tolerance for manual work — then build the foundation underneath it properly, because that's the part that decides whether either one lasts.